Medincell Stock Rises Over 2% and Extends Its Rebound to 12% Over a Month
The biotech company from Montpellier continues its recovery in late morning trading, in a Parisian market trending upwards. The stock benefits from new analyst support, adding to an already very favorable annual trajectory.
Portzamparc Raises Its Target to €30 and Reaffirms Its Buy Recommendation
Medincell gains 2.24% to €27.44 during the session, while the SBF 120 index is up 0.29%. This movement occurs as Portzamparc increased its price target from €29.20 to €30.00 on June 3, maintaining its buy recommendation. Based on the current price, this new target offers a potential of about 9.3%. Regarding the pipeline, the European file for olanzapine LAI developed with Teva was accepted by the EMA at the end of May, a step already integrated by the market.
The Stock Remains Above Its Moving Averages Despite a Weekly Decline
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
At €27.44, the stock is above its 20-day moving average of €27.14 and maintains a comfortable gap with its 50-day moving average at €25.02 (+9.67%). The progress reaches nearly 12% over a month and 71.6% over a year, indicating a solid underlying momentum despite a weekly decline of 3.52%. The RSI at 53 indicates a balance between buyers and sellers, without excess. The resistance of €28.72, already surpassed at the end of May and then lost at the beginning of June, remains the next graphical threshold to monitor to extend the rebound. The technical support reference is at €22.86, more than 16% below the current price.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
